Silverarc Capital Management, LLC Arvinas, Inc. Transaction History

Silverarc Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 28, 2022	BUY	$41.87 - $57.99 $1.71 Million - $2.36 Million	40,741 New	40,741 $1.81 Million
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $2.45 Million - $3.58 Million	-37,249 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $2.73 Million - $4.02 Million	37,249 New	37,249 $3.06 Million
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $1.52 Million - $2.11 Million	-25,071 Closed	0 $0
Q1 2021 May 18, 2021	SELL	$58.19 - $91.37 $1.74 Million - $2.73 Million	-29,929 Reduced 54.42%	25,071 $1.66 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $1.11 Million - $4.67 Million	55,000 New	55,000 $4.67 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.